polypoidal choroidal vasculopathy
Conditions
Interventions
1) Study period start at the day of the first injection of aflibercept. 2) Aflibercept is injected 3 monthly as an induction phase. 3) Aflibercept is injected 4 bimonthly as a maintenance phase foll
Sponsors
Yokohama City University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with informed consent 2) Patients with both sexes whose age are 50 or over 3) Patients with exudative age-related macular degeneration 4) Patients who is diagnosed as PCV on fundus photo or ICGA 5) Patients without previous treatment for PCV 6) Dicimal visual acuity of the study eye is between 0.1 and 0.7
Exclusion criteria
Exclusion criteria: 1) Lesion size >=12 disc area (1 disc rea is 30.5mm2). 'Lesion' includes hemorrhage, scar, and CNV. 2) Area of subretinal hemorrage in study eye>=50% of total lesion area 3) Area of scar or fibrosis in study eye>=50% of total lesion area 4) RPE tear in study eye 5) Stage 3 or 4 macular hole in study eye 6) Administration of triamcinolone to study eye within 6 months prior to this study 7) Administration of dexamethasone to study eye within 30 days prior to this study 8) Intraocular surgery to study eye within 6 months prior to this study 9) Any history of vitrectomy in study eye 10) Any inflammation or infection in intra-or extra-ocular tissue in either eye 11) History of uveitis in either eye 12) Allergy to fluorescein, indocyanine or iodine 13) pregnant women and nursing mothers 14) Patients who were judged by docters to be inappropriate for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ratio of patients who achieved less than 15 letters loss in ETDRS chart | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of visual acuity in ETDRS chart between baseline and 6 or 12 months after treatment Ratio of polyp regression on ICGA at 6 or 12 months after treatment Ratio of abnormal vascular network regression on ICGA at 6 or 12 months after treatment Change of foveal thickness on OCT between baseline and 6 or 12 months after treatment Change of exudative lesions between baseline and 6 or 12 months after treatment | — |
Countries
Japan
Contacts
Public ContactAkira Arakawa
Yokohama City University Medical Center Ophthalmology
Outcome results
None listed